tbuckley/cabot-search huggingface dataset:
AB0858 PREVALENCE AND SIGNIFICANCE OF NAILFOLD CAPILLAROSCOPY ABNORMALITIES IN PRIMARY SJOGREN’S SYNDROME COMPARED TO PRIMARY RAYNAUD PHENOMENON
Authors: I. W. Hong, H. S. Kim, K. A. Lee
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Raynaud's phenomenon (RP) is known to coexist in 13-30% of patients with primary Sjogren's syndrome (pSS). Studies on findings of nailfold capillaroscopy (NFC) in pSS are limited. <h3>Objectives:</h3> This single-center, retrospective study aimed to 1) evaluate the NFC features compared to primary RP, and 2) analyze the association between microvascular abnormalities and clinical features in patients with pSS. <h3>Methods:</h3> We included patients with pSS who fulfilled the 2016 ACR/EULAR classification criteria and patients with primary RP who underwent NFC between 2016 and 2022. Clinical manifestations, laboratory findings, pulmonary function tests, and chest computed tomography findings were collected for each patient, and they were observed until the last follow-up or death. NFC findings were classified into three groups according to the fast track algorithm proposed by the EULAR Study Group: normal, non-specific abnormalities, and scleroderma pattern. <h3>Results:</h3> A total of 223 patients were included: pSS (n=140), and primary RP (n=83). RP in pSS was observed in 35 patients (25%). Patients with pSS showed significantly more non-specific abnormalities (50.7% vs. 32.5%) and scleroderma pattern (7.8% vs. 0%) than those with primary RP (<i>p</i>&lt;0.001). Abnormal density (<i>p</i>&lt;0.001), giant capillary (<i>p</i>&lt;0.05), and abnormal morphology (<i>p</i>&lt;0.001) were more detected in pSS patients. Among the pSS group, patients with microvascular abnormalities had a higher presence of RP (35.3% vs. 10.3%, <i>p</i>&lt;0.01) and interstitial lung disease (ILD) (35.3% vs. 6.8%, <i>p</i>&lt;0.001), as well as a higher positivity for anti-Ro52/SSA (58.5% vs. 29.3%, <i>p</i>&lt;0.01), than those with a normal NFC pattern. When comparing ILD features in patients with pSS-ILD, forced vital capacity (69.5% vs. 96%, <i>p</i>&lt;0.05) and diffusing capacity of the lung for carbon monoxide (56.5% vs. 83.0%, <i>p</i>&lt;0.05) at the last follow-up were lower in patients with microvascular abnormalities than those with a normal pattern. <h3>Conclusion:</h3> Microvascular abnormalities were more common in patients with pSS compared to those with primary RP. pSS patients with microvascular abnormalities had more RP, anti-Ro52, ILD, and impaired lung function. <h3>REFERENCES:</h3> [1] Smith V, Vanhaecke A, Herrick AL, et al. Fast track algorithm: How to differentiate a "scleroderma pattern" from a "non-scleroderma pattern". Autoimmunity reviews 2019;18:102394. <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB1010 DRUG-INDUCED LUPUS: CLINICAL AND SEROLOGICAL FEATURES IN A TERTIARY HOSPITAL
Authors: S. Leal Rodriguez, I. Alcántara Álvarez, M. De la Rubia Navarro, L. González Puig, E. Grau García, A. V. Huaylla Quispe, J. Ivorra, I. Martínez Cordellat, L. Mas Sanchez, P. Muñoz Martínez, R. Negueroles Albuixech, J. E. Oller Rodríguez, D. Ramos Castro, C. Riesco Barcena, A. M. Torrat Noves, E. Tovar Sugrañes, E. Vicens Bernabeu, B. Villanueva Mañes, I. Cánovas Olmos, C. Nájera Herranz, J. A. Román Ivorra
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Several drugs have been implicated in the development of <i>de novo</i> systemic lupus erythematosus (SLE), unmasking of quiescent SLE or causing an exacerbation of previously diagnosed SLE. <h3>Objectives:</h3> Our aim is to describe the causative drugs, clinical and serological features of patients diagnosed of Drug-Induced lupus (DIL) in our Rheumatology Department <h3>Methods:</h3> A total of 445 patients diagnosed with SLE treated in our Rheumatology Department from 2012 to 2023 were retrospectively screened for the fulfilment of DIL criteria through the search of medical electronic records. Demographic, clinical and laboratory data were summarised using descriptive statistics <h3>Results:</h3> We identified 18 patients diagnosed with DIL, representing a prevalence of 4% among all SLE patients in our department. There was a female preponderance and a young age at disease onset. Patients' clinical and serological characteristics are shown in Table 1. Only three drugs (infliximab, adalimumab and sulfasalazine) were identified as causative agents of DIL, anti-TNF being the most common. Most patients were treated for a condition different from a rheumatic disease, mainly inflammatory bowel disease (IBD). Median time to symptom onset after drug initiation ranged from 3 to 194 weeks (median 50.4). Peripheral arthritis and skin rash were the most frequent symptoms, with 4 patients (22%) presenting both at onset. Serologically, only 2 patients were ANA negative, but tested positive for anti-dsDNA. After drug withdrawal, ANA titre showed a slow decreasing trend over time, as well as anti-dsDNA antibodies. However, only 2 patients lost ANA-positivity through follow-up. Remarkably, more than half of the patients tested positive for antiphospholipid antibodies. <h3>Conclusion:</h3> DIL showed a prevalence of 4% among SLE cases in our Rheumatology Department. Anti-TNF agents were the most common drugs related to DIL. ANA tended to decrease over time, but only become undetectable in a few patients. Antiphospholipid antibodies are common in our DIL patients. Age at onset is earlier than previously reported, probably because causative drugs are being used in younger populations. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB1083 PREDICTORS OF LLDAS AND REMISSION IN A SINGLE-CENTER COHORT OF PATIENTS WITH LUPUS NEPHRITIS: A RETROSPECTIVE ANALYSIS
Authors: F. Cirilli, C. Garaffoni, G. Galoppini, E. Silvagni, M. Govoni, A. Bortoluzzi
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> <b>Lupus nephritis (LN), a major involvement of systemic lupus erythematosus (SLE), impacts up to 60% of SLE patients throughout their lives, with a progression rate to end-stage kidney disease ranging from 4.3% to 10.1%.</b> <h3>Objectives:</h3> <b>This study aims to 1) assess the attainment of lupus low disease activity state (LLDAS) and remission in SLE patients with LN at a single center and 2) analyze predictors of LLDAS, remission, and stage ≥3 chronic kidney disease (CKD).</b> <h3>Methods:</h3> <b>This retrospective, observational study included SLE patients diagnosed since 1977 with documented renal involvement via kidney biopsy. Demographic, clinical, and laboratory data were collected from the onset of renal disease to the last outpatient visit. CKD was defined as eGFR (calculated using CDK-EPI formula) ≤60 mL/min/m2, while LLDAS and REM definitions were based on criteria by Franklyn K. et al (Ann. Rheum. Dis., 2016) and van Vollenhoven RF (Lupus Sci. Med., 2021).</b> <h3>Results:</h3> <b>The study comprised 87 patients, with 42 having proliferative glomerulonephritis (see Table 1). During the follow-up, clinical remission was achieved in 63 out of 83 (75.9%) patients, and LLDAS in 73 out of 85 (85.9%) patients, with an average time of 8.46 (±8.67) and 8.33 (±8.96) months between biopsy diagnosis and achieving remission and LLDAS, respectively. Univariate analysis indicated a statistically significant association between higher SLEDAI-2K and failure to achieve LLDAS (OR 0.88, p 0.049). The occurrence of at least one LN flare during follow-up was associated with a lower probability of achieving LLDAS (OR 0.17, p 0.01) but not remission (OR 0.29, p 0.05). Predictors of stage ≥3 CKD included a longer time between LN diagnosis and LLDAS/REM achievement (OR 1.08, p 0.02/OR 1.09, p 0.01), a higher SDI score (OR 1.82, p 0.02), and the protective effect of hydroxychloroquine use (OR 0.26, p 0.02).</b> <h3>Conclusion:</h3> <b>In our cohort, higher SLEDAI-2K scores and the occurrence of LN flares were associated with a lower probability of response to therapy. A higher SDI score and a prolonged time to achieve REM/LLDAS serve as potential indicators of kidney function deterioration.</b> <h3>REFERENCES:</h3> <b>[1] Gasparrotto M et al (Rheumatology Oxford, 2020), Franklyn K. et al (Ann. Rheum. Dis., 2016), van Vollenhoven RF (Lupus Sci.Med.,2021).</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB1030 JAK INHIBITORS’ EFFICACY AND SAFETY IN SYSTEMIC LUPUS ERYTHEMATOSUS: SYSTEMATIC REVIEW AND META-ANALYSIS
Authors: R. Dos-Santos, C. Porto, E. Perez-Pampín, J. R. Maneiro, P. Castro-Santamaria, M. Sanchez-Wonenburger, J. L. Puga-Guzmán, A. Mata, I. Álvarez, E. Campos, A. Mera Varela
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Even new drugs have been pointed up last years for Systemic Lupus Erythematosus (SLE) treatment, new and direct targets are currently an unmet accomplishment in the management of the disease. Improvement of disease activity and quality of life of SLE patients is, many times, an unreachable goal in daily clinical practice.<sup>1</sup> Janus-kinase inhibitors (JAKi) have been approved for treating several immune-mediated diseases such as rheumatoid arthritis or spondyloarthritis. Its mechanism of action seems to be beneficial in a cluster of SLE patients.<sup>2</sup> <h3>Objectives:</h3> To assess JAKi efficacy and safety for SLE treatment. <h3>Methods:</h3> A systematic review of the literature was made up to November 2023 in 4 databases (Medline, Embase, The Cochrane Library, Web of Science). Eligibility criteria were SLE patients at treatment with any JAKi. A meta-analysis was performed when at least 2 results with comparable measurements were found. <h3>Results:</h3> After review of 1080 studies found, 8 studies were finally included. Only 3 random clinical trials assessed efficacy and safety of Baricitib in SLE. Baricitinib 4 mg showed a significant improvement in global activity index as SRI-4 (OR 1.37; CI95% 1.05, 1.79; p=0.020) and SLEDAI-2K (SMD -2.41; CI95% -4.31, -0.51; p=0.013) (Figure 1). As well, a significant improvement in patients' joint activity (regarding SJC, TJC and WJP) and fatigue (regarding FACIT-F) was found (p&lt;0.05). Most of adverse events reported in the Baricitinib arm were mild or moderate in severity. A significant greater amount of patients treated with Baricitinib reported severe adverse events compared to placebo (Figure 2). <h3>Conclusion:</h3> Our meta-analyzed results support the potential benefit of JAKi, particularly Baricitinib, in SLE treatment, especially in joint involvement. Our data is insufficient for making a strong recommendation, and further investigations are needed in this field. <h3>REFERENCES:</h3> [1] Fava A, Petri M. Systemic lupus erythematosus: Diagnosis and clinical management. <i>J Autoimmun</i>. 2019;96:1-13. [2] Alunno A, Padjen I, Fanouriakis A, Boumpas DT. Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent. <i>Cells</i>. 2019;8(8):898. <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB0859 A SINGLE-CENTRE EXPERIENCE WITH SJÖGREN’S DISEASE AND SARS-CoV-2
Authors: K. Perdan-Pirkmajer, L. Furjanič, M. Tomšič, A. Hocevar, S. Praprotnik, S. Pirkmajer
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Sjögren's disease (SD) patients have some specific features that could make them even more prone to <i>SARS-CoV-2</i> infection (mucosal dryness, altered exocrine gland excretions), but the data are limited. <h3>Objectives:</h3> The aim of our study was to determine clinical and epidemiological characteristics of <i>SARS-CoV-2</i> infection in a well-defined cohort of patients with SD. <h3>Methods:</h3> Our cohort consisted of patients diagnosed with SD based on the ACR/EULAR 2016 classification criteria<sup>1</sup> between January 2016 and December 2019. Patients were regularly followed at our secondary/tertiary centre. In March 2022 retrospective reviews of patient's medical record were performed, searching for any information about the confirmed <i>SARS-CoV-2</i> infection in the period between March 2020 and February 2022. All patients with a confirmed <i>SARS-CoV</i>-2 infection were contacted by phone to fulfill a questionnaire regarding their infection course (mild disease or severe disease - latter defined as need of hospitalization, thrombotic events, due to <i>SARS-CoV-2</i> infection or death). Descriptive statistics were used to explore the studied population by using SPSS version 27. <h3>Results:</h3> In our cohort of 169 SD patients (94% female, median age 60.5 [IQR: 51-69, range: 23-88]) 66 patients had at least one <i>SARS-CoV</i>-2 infection documented (39 %), in most patients (48/66, 72.7 %) the infection course was mild. Five patients (7.5%) had severe infection requiring hospitalization (3 patients between March and December 2021 and 2 patients in early 2022). There were no deaths and thrombotic events due to infection. The comparison of characteristics of <i>SARS-CoV</i>-2 infected group to <i>SARS-CoV</i>-2 negative group (Table 1) showed that males and younger patients were more at risk for <i>SARS-CoV</i>-2 infection. We found no differences in unstimulated salivary flow test, Schirmer's test, Rose Bengal test or baseline ESSDAI between SD patients with and without SARS COV-2 infection. <h3>Conclusion:</h3> Almost 40 % of our SD patients had at least one <i>SARS-CoV</i>-2 infection during the 24 month observation period. Younger males were at greater risk of COVID-19, but we did not find any association between the objective severity of mucosal dryness nor baseline systemic disease activity and the risk of SARS-COV-2 infection. <h3>REFERENCES:</h3> [1] Shiboski CH, et al. Arthritis Rheumatol 2017;69:35–45. <b>Table 1.</b> Clinical and laboratory characteristics of SD patients with and without SARS-CoV-2 infection BMI – Body Mass Index, USF – Unstimulated Salivary Flow, CRP – C-reactive protein, ESR – Elevated Sedimentation Rate, aENA – Anti-Extractable Nuclear Antigen Antibody, RF – Rheumatoid Factor, ESSDAI – EULAR Sjögren's syndrome disease activity index <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB0855 SJÖGREN SYNDROME: PREVALENCE OF PERIPHERAL NEUROLOGICAL MANIFESTATIONS DURING DISEASE PROGRESSION
Authors: M. Pallo, A. Marcé, V. Bejarano, L. Ingolotti, C. Amitrano, C. Asnal, P. Pucci, D. Duartes Noé, A. Gomez, A. Rollano Perasso, S. Zalles, F. Caeiro, L. Degioanni, V. Saurit, C. Gobbi, L. Alascio, S. Papasidero, V. C. Cruzat, L. Raiti, G. Salvatierra, V. Juarez, M. L. Santiago, S. Velez, A. Secco
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Primary Sjogren´s syndrome (pSS) is an autoimmune disease that presents systemic manifestations one of the most significant is tehe involvement of the peripheral nervous system. It may appear as the onset of SSp, although the most severe forms occur as a late manifestation. <h3>Objectives:</h3> Describe the frequency of patients with pSS debuting with PNS involvement and those developing it during follow-up. Compare disease progression between patients with this involvement and those without, and between those debuting with PNS involvement versus those developing it during follow up. <h3>Methods:</h3> Observational, analytical, multicenter cross- sectional study. Included patients diagnosed with pSS according to ACR-EULAR 2016 and/or American-European 2002 classification criteria, aged 18 or older, and registered in the GESSAR group database who had at least one consultation. Patients with other autoimmune diseases and those with prior neurological pathology or attributable to other causes were excluded. <h3>Results:</h3> 681 patients were included with a mean age of 54 years (± 14), 95% female, with a mean follow-up of 4.6 years (±5). 10.57% presented PNS commitment; In 8.33% it was the debut of the disease. In the bivariate analysis, comparing patients with and without PNS manifestations, statistically significant differences were found in: Age (mean: 58 vs 54 p. 0.03), Arthritis (OR 1.93 95% CI 1.17- 3.18), Purpura (OR 2.59 95% CI 1.22-5.47), Raynaud (OR 2.06 95% CI 1.15-3.69), C3 (OR 2.08 95% CI 1.01- 4.31), C4 (OR 2.15 95% CI 1.18- 3.92), corticosteroids use (OR 1.84 95% CI 1.04-3.24), immunosuppressive drugs use (OR 2.05 95% CI 1.17 – 3.59). In the multivariate analysis, a significant and independent association was found with age (OR 1.02 95% CI 1- 1.04), arthritis (OR 1.89 95% CI 1.13-3.18), purpura (OR 2.31 95% CI 1.05-5.05) and Raynaud (OR 2 95% CI 1.10-3.66). No statistically significant differences were found when comparing PNS involvement at onset vs. during follow-up. <h3>Conclusion:</h3> We observed a frequency of PNS involvement within the range reported in the literature. Comparing both groups, we observed greater systemic involvement in patients with this manifestation; suggesting closer monitoring of this patient subgroup. <h3>REFERENCES:</h3> <b>NIL</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB0909 SEX- RELATED DIFFERENCES IN EFFICACY OF BIOLOGICS IN AXIAL SPONDYLOARTHRITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS
Authors: M. Magrey, O. Pamuk, S. Abi Doumeth, A. Daoud, M. Shamim, H. Chaudhary
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> There is limited information about sex-related differences in efficacy of biologics in axial spondyloarthritis (axSpA). <h3>Objectives:</h3> We hypothesized that females with axSpA are less likely to respond to biologics compared to men with axSpA. We aimed to compare the efficacy of biologics among men and women with axSpA both from clinical trials and real-world studies.. <h3>Methods:</h3> A comprehensive literature search was conducted using electronic databases, including PubMed, Embase, and Cochrane Library, and screening the EU clinical trial registry to identify relevant studies published until November 2023. Clinical trials and real world studies reporting BASDAI50, ASDAS, ASAS-40 disease indices were included. Both radiographic and non-radiographic axSpA treatment studies with different biologic therapies (TNF-i, and IL-17-i) for 6 months to 1 year were included. The risk of bias was assessed using the Cochrane risk of bias tool. Two independent reviewers screened the articles, and the senior author did conflict resolution. Data were extracted and analyzed using R Statistical Software meta package (v4.2.1; R Core Team 2022) to calculate odds ratios for male vs female treatment responses (95% CI). <h3>Results:</h3> We screened 1661 articles and included 11 studies, 8 of TNFi and 3 of IL-17i as shown in PRISMA flow diagram (Figure 1a). Total number of patients with axSpA were 11,199, of which 4121 (36.8%) were females. The baseline characteristics of the studies are shown in Table 1. HLA-B*27 positivity was more common in males, pooled OR 1.58 (95% CI:1.45-1.72). BASDAI 50 response, pooled OR 1.91 (95% C1: 1.45: 2.49) and ASDAS low disease activity response, pooled OR of 1.70 (95% C1: 1.18-2.47) showed significantly higher odds for male response to the therapy in both common effect and random effect model as shown in the Figure 1 (b) and (c), five studies each. There was no gender based difference in ASAS40 responses in seven studies with, OR 1.00 (95% CI: 0.59-1.71). <h3>Conclusion:</h3> Male patients with axSpA treated with biologics achieved higher BASDAI50 response and were more likely to achieve ASDAS low disease activity compared to females with axSpA, suggesting sex based differences in treatment outcomes may exist. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> Marina Magrey Pfizer, Novartis, Eli Lilly, Pfizer, Abbvie, Janssen, UCB Pharma, BMS, Omer Pamuk: None declared, Sarah Abi Doumeth: None declared, Ansaam Daoud: None declared, Muhammad Shamim: None declared, Haseeb Chaudhary: None declared.
AB1234 HIGHER EDUCATION AND THE LACK OF DIGITAL ULCERS ARE ASSOCIATED WITH EMPLOYMENT IN A COHORT OF PATIENTS WITH SYSTEMIC SCLEROSIS
Authors: C. Vrancianu, C. Grigore, E. D. Popa, E. M. Hoinoiu, I. Ancuta, M. Bojinca, A. M. Gheorghiu
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Systemic sclerosis (SSc) is a multisystem chronic autoimmune disease, which leads to disability and possibly early retirement. <h3>Objectives:</h3> To investigate the association between employment status (ES) and disease features in an EUSTAR single-center cohort of patients with SSc. <h3>Methods:</h3> Consecutive SSc patients who were under the age of retirement in our country (62 years for women, 65 for men at the time) were examined in our center between the periods 11.2011-06.2023. Patients had a full SSc assessment and also filled in a work assessment questionnaire and two other health-related questionnaires. The associations between ES and potential predictors, such as socio-economic status, education, disease characteristics and health-related questionnaires) were tested using logistic regression adjusted for age and gender. <h3>Results:</h3> Ninety-one patients (mean±SD age 53.7±11.8 years, 22 with diffuse skin involvement, 56 with a history of digital of digital ulcers (DUs)) were included. Sixty-nine patients were retired, of which 38 because of SSc. Of those in employment, 23 spent many hours standing, 23 did manual labor and 14 had to work in a cold environment. Higher education (high school or above) and lack of history for DUs were highly associated with employment (OR (95%CI) 11.08(1.9, 61.6)), respectively 4.5 (1.3, 15.5). There were no associations of ES with patient-reported outcome measurements. <h3>Conclusion:</h3> SSc is associated with significant work disability and unemployment. Completing higher education, defined as high school or university, and the lack of history for DUs were highly associated with staying employed. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>